

Table S1. List of mice subjected to intermittent erlotinib treatment

Mouse number	Genotype	Difference in lung tumor volume	
		First round of treatment	Final round of treatment
K8774	<i>C/L858R57</i>	91% decrease	n.d.
K8397	<i>C/L858R57</i>	n.d.	n.d.
K6944	<i>C/L858R56</i>	T1=6% decrease/T2=90% decrease	T1=2% increase/T2=42% decrease
K8404	<i>C/L858R57</i>	43% decrease	11% decrease
K9789	<i>C/L858R57</i>	n.d.	n.d.
K9614	<i>C/L858R57</i>	n.d.	n.d.
K15240	<i>C/L858R56 Trp53+/-</i>	n.d.	n.d.
K6585	<i>C/L858R56 Trp53+/-</i>	90% decrease	54% decrease*
K8405	<i>C/DEL9</i>	65% decrease	8% decrease
K8043	<i>C/DEL11/p53+/-</i>	n.d.	n.d.
K6678	<i>C/DEL9 Ink4a/Arf+/-</i>	94% decrease	55% decrease*

*In these mice, increases in tumor volume of 43% (K6678) and 275% (K6585) were observed when erlotinib treatment was prolonged beyond 4 weeks in the final treatment round.

T1=tumor 1, T2=tumor 2; n.d., not determined.